1. Show article details.

    Novel Preventative Solutions Seek to Curtail the Spread of the Pandemic

    PR Newswire – 9:00 AM ET 01/19/2022

    NEW YORK, Jan. 19, 2022 The number of people infected by the Omicron variant of COVID-19 has broken records since the new year had started. In the meantime, in New York, which is once again the epicenter of the pandemic in the U.S., it was announced that city officials are negotiating a temporary return to remote learning for tens of thousands of students who aren't showing up for class.

  2. Show article details.

    Diagnostics Remain Vital Despite a Growing Number of Vaccinated

    PR Newswire – 9:00 AM ET 01/11/2022

    NEW YORK, Jan. 11, 2022  While the pandemic continues to be highly contagious, more so than before due to the Omicron variant, vaccines and testing on a regular basis remain crucial aspects in the fight against the spread. Because tests are a necessary tool to understand the spread of the pandemic and also to predict its prognosis, COVID tests are now in short supply.

  3. Show article details.

    Innovative Products Emerge to Mitigate Concerns Over the Pandemic's Longevity

    PR Newswire – 9:00 AM ET 01/06/2022

    NEW YORK, Jan. 6, 2022 The pandemic's longevity has renewed concerns as new variants are becoming more prominent around the globe.

  4. Show article details.

    Vaxart to Participate at the H.C. Wainwright BioConnect Virtual Conference

    GlobeNewswire – 8:00 AM ET 01/04/2022

    Vaxart, Inc. (VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a virtual fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022.

  5. Show article details.

    Spread of New Variant Reinforces the Need for Comprehensive Diagnostics

    PR Newswire – 9:00 AM ET 12/23/2021

    NEW YORK, Dec. 23, 2021  Concerns begin to resurface as the Omicron variant has proven to be a highly contagious continuation of the pandemic. Even though vaccines are readily available and are being rolled out around the globe, testing remains a crucial factor.

  6. Show article details.

    A Sharp Uptick in Infections Reignites Fears of New Restrictions

    PR Newswire – 9:00 AM ET 12/17/2021

    NEW YORK, Dec. 17, 2021 The ongoing pandemic is causing renewed concerns as new variants are becoming more prominent. As a result of the most recent surge, schools like New York University and Cornell University have canceled in-person events and shifted finals online.

  7. Show article details.

    Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron

    GlobeNewswire – 8:00 AM ET 12/16/2021

    Cross-reactivity will be assessed using samples from Phase II clinical participants and in a parallel animal challenge study Oral tablet’s immunogenicity profile suggests it may provide cross-protection against SARS-CoV-2 variants, including Omicron SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 -- Vaxart (VXRT), Inc. said today it plans to test the cross-reactivity of its oral tablet COVID-19 vaccine ...

  8. Show article details.

    BRIEF-Vaxart Inc To Purchase Kindredbio's Manufacturing Equipment And Sublease Of Its GMP Manufacturing Facility In Burlingame

    Reuters – 8:28 AM ET 12/01/2021

    Vaxart Inc (VXRT): * Vaxart Inc (VXRT) - TO PURCHASE KINDREDBIO'S MANUFACTURING EQUIPMENT AND SUBLEASE OF ITS GMP MANUFACTURING FACILITY IN BURLINGAME. * Vaxart Inc (VXRT) - EXPECTS FACILITY TO BE OPERATIONAL FOR GMP PRODUCTION IN Q1 2022 Source text for Eikon: Further company coverage:

  9. Show article details.

    Vaxart Announces Acquisition of Second GMP Manufacturing Facility

    GlobeNewswire – 8:00 AM ET 12/01/2021

    Vaxart (VXRT), Inc. has entered into an agreement with Kindred Bioscience, Inc. for the purchase of KindredBio’s manufacturing equipment and sublease of its GMP manufacturing facility in Burlingame, California, giving Vaxart (VXRT) control of its second GMP manufacturing facility. The transaction closed Tuesday, Nov. 30, 2021, and Vaxart (VXRT) expects the facility to be operational for GMP production in Q1 2022.

  10. Show article details.

    Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2021 on November 30, 2021 

    GlobeNewswire – 8:00 AM ET 11/23/2021

    Vaxart, Inc. (VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2021 in San Diego on Tuesday, November 30, 2021 at 2:40 p.m. PT. Dr. Tucker will provide an overview of Vaxart’s development program for its oral tablet COVID-19 vaccine candidate.

  11. Show article details.

    Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart

    GlobeNewswire – 4:02 PM ET 11/18/2021

    A new Stanford study published in Cell Host and Microbe has demonstrated that VXA-A1.1, an investigational oral tablet flu vaccine under development by Vaxart, Inc. (VXRT), had cellular correlates of protection against influenza infection.1 These cellular correlates were found using mass cytometry analysis of vaccine-elicited cellular immune responses in the peripheral blood of participants in a previ...

  12. Show article details.

    BRIEF-Vaxart Announces Publication Of Complete Data From Preclinical COVID-19 Oral Vaccine Hamster Challenge Study

    Reuters – 9:53 AM ET 11/16/2021

    Vaxart Inc (VXRT): * VAXART ANNOUNCES PUBLICATION OF COMPLETE DATA FROM PRECLINICAL COVID-19 ORAL VACCINE HAMSTER CHALLENGE STUDY IN JOURNAL OF INFECTIOUS DISEASES Source text for Eikon: Further company coverage:

  13. Show article details.

    Vaxart Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study in Journal of Infectious Diseases

    GlobeNewswire – 8:00 AM ET 11/16/2021

    Vaxart, Inc. (VXRT) announced today the Journal of Infectious Diseases has published complete data from Vaxart’s preclinical Hamster Challenge Study.

  14. Show article details.

    Vaxart to Participate at Upcoming Conferences

    GlobeNewswire – 4:01 PM ET 11/11/2021

    Vaxart, Inc. (VXRT) today announced that Andrei Floroiu, President and CEO, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will be participating in virtual fireside chats at the following conferences: Webcasts of both fireside chats will be available on the Company’s Events & Presentations page, accessible here: https://investors.vaxart.com/events-p...

  15. Show article details.

    Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results

    GlobeNewswire – 4:01 PM ET 11/04/2021

    Four clinical trials for COVID-19 and norovirus oral tablet vaccine candidates are currently ongoing Company now operates two GMP manufacturing plants to support rapid clinical advancement of pipeline programs Ended the quarter with $204 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 -- Vaxart (VXRT), Inc. issued its business update today for th...

  16. Show article details.

    BRIEF-Vaxart Doses First Subject In Phase II Covid-19 Oral Tablet Vaccine Clinical Trial

    Reuters – 8:39 AM ET 10/26/2021

    Vaxart Inc (VXRT): * VAXART DOSES FIRST SUBJECT IN PHASE II COVID-19 ORAL TABLET VACCINE CLINICAL TRIAL Source text for Eikon: Further company coverage:

  17. Show article details.

    Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet Vaccine Clinical Trial

    PR Newswire – 8:00 AM ET 10/26/2021

    SOUTH SAN FRANCISCO, Calif. the United States in the first part of its Phase II trial. "Dosing the first subjects with the most advanced oral tablet COVID-19 vaccine candidate marks another important step forward toward developing a transformative solution to the SARS-CoV-2 global pandemic," said Andrei Floroiu, Vaxart's Chief Executive Officer.

Page:

Today's and Upcoming Events

  • Feb
    23

    VXRT to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Nov
    04

    VXRT announced Q3 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.